Medical Oncology

, Volume 24, Issue 4, pp 379–383

The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas

  • Meral Y. Sayin
  • Bektas Kaya
  • Bekir H. Bakkal
  • Kadri Altundag
  • Muzaffer B. Altundag
Clinical Study


In this prospective study, we investigated the effects of hypofractionated radiotherapy for patients with high-grade gliomas. About 31 patients with glioblastoma multiforme or anaplastic astrocytoma were studied between October 2003 and December 2004. Hypofractionated radiotherapy (3 Gy/fraction/day) was delivered to a total dose of 45 Gy in 15 fractions in 10 patients (32%) who had total excision before radiotherapy and to a total dose of 54 Gy in 18 fractions in 21 patients (68%) who had subtotal excision or biopsy alone. Sex, age, type of surgery, tumor grade, Karnofsky performance status, time between surgery and initiation of radiotherapy, and total radiotherapy dose were analyzed as potential prognostic factors for survival using the univariate log-rank method. The median follow-up was 15 months (4–16 months). A total of 15 patients (48%) died of their illness; 16 patients (52%) were still alive at the last follow-up. The median survival time was 8 months. Actuarial 1–year overall survival was 40%. Type of surgery, timing of radiotherapy after surgery, and initial Karnofsky performance status were significant prognostic factors for survival. No grade 3–4 acute or late neurotoxicity was observed. The tolerance of patients to hypofractionated RT was not different from that for conventional radiotherapy. This treatment schedule can be used for patients with high-grade gliomas. Future investigations are needed to determine the optimal fractionation for high-grade gliomas.


Glioblastoma multiforme Anaplastic astrocytoma Hypofractionated radiotherapy 


  1. 1.
    Scally TL, Lin C, Beriwal S, Brady WL. Brian, brain stem, and cerebellum In: Perez CA, Brady LW, (editors) Principles and practice of radiation oncology 4th ed. Philadelphia: Lippincott-Raven Publishers; 2004. pp. 810–815.Google Scholar
  2. 2.
    Gehan EA, Walker MD. Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr 1977;46:189–195.PubMedGoogle Scholar
  3. 3.
    Simpson JR, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239–244.PubMedGoogle Scholar
  4. 4.
    Nitta T, Sato K. Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 1995;75:2727–2731.PubMedCrossRefGoogle Scholar
  5. 5.
    Walker MD, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323–1329.PubMedCrossRefGoogle Scholar
  6. 6.
    Prados MD, et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 1992;23:3–8.PubMedGoogle Scholar
  7. 7.
    Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988;6:338–343.PubMedGoogle Scholar
  8. 8.
    Kernohan JW, Sayre GP. Tumors of the central nervous system. In: Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology; 1952. pp. 43–59.Google Scholar
  9. 9.
    Wisoff JH, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 1998;89:52–59.PubMedCrossRefGoogle Scholar
  10. 10.
    Halperin EC. Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it. Oncology 1995;9:229–234.PubMedGoogle Scholar
  11. 11.
    Kleinberg L, et al. Short course radiotherapy is an appropriate option for most malignant glioma patients. Int J Radiat Oncol Biol Phys 1997;38:31–36.PubMedCrossRefGoogle Scholar
  12. 12.
    Bauman GS, et al. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1994;4:835–839.Google Scholar
  13. 13.
    Hercbergs AA, Tadmor R, Findler G, Sahar A, Brenner H. Hypofractionated radiation therapy and concurrent cisplatin in malignant cerebral gliomas. Rapid palliation in low performance status patients. Cancer 1989;64:816–820.PubMedCrossRefGoogle Scholar
  14. 14.
    Hulshof MC, Schimmel EC, Bosch DA, Gonzalez DG. Hypofractionation in glioblastoma multiforme. Radiother Oncol 2000;54:143–148.PubMedCrossRefGoogle Scholar
  15. 15.
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341–1346.PubMedCrossRefGoogle Scholar
  16. 16.
    Lonardi S, Tosoni A, Brandes AA. Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev 2005;31:79–89.PubMedCrossRefGoogle Scholar
  17. 17.
    Thomas R, et al. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother Oncol 1994;33:113–116.PubMedCrossRefGoogle Scholar
  18. 18.
    Slotman BJ, Kralendonk JH, van Alphen HA, Kamphorst W, Karim AB. Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors. Int J Radiat Oncol Biol Phys 1996;34:895–398.PubMedCrossRefGoogle Scholar
  19. 19.
    Sultanem K, et al. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys 2004;58:247–252.PubMedCrossRefGoogle Scholar
  20. 20.
    Floyd NS, et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2004;58:721–726.PubMedCrossRefGoogle Scholar
  21. 21.
    Ammirati M, Vick N, Liao YL, Ciric IL, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 1987;21:201–206.PubMedCrossRefGoogle Scholar
  22. 22.
    Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993;78:762–766.PubMedCrossRefGoogle Scholar
  23. 23.
    Miller PJ, et al. Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors. Int J Radiat Oncol Biol Phys 1990;19:275–280.PubMedGoogle Scholar
  24. 24.
    Curran WJ Jr, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant gliomas trials. J Natl Cancer Inst 1993;85:704–710.PubMedCrossRefGoogle Scholar
  25. 25.
    Wara WM. Radiation therapy for brain tumors. Cancer 1985;55:2291–2295.PubMedCrossRefGoogle Scholar
  26. 26.
    Hudes RS, et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 1999;43:293–298.PubMedCrossRefGoogle Scholar
  27. 27.
    Chang EL, et al. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 2003;56:519–528.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Meral Y. Sayin
    • 1
  • Bektas Kaya
    • 1
  • Bekir H. Bakkal
    • 1
    • 3
  • Kadri Altundag
    • 2
  • Muzaffer B. Altundag
    • 1
  1. 1.Department of Radiation OncologyAnkara Oncology HospitalAnkaraTurkey
  2. 2.Department of Medical OncologyHacettepe University Institute of OncologyAnkaraTurkey
  3. 3.Kozlu-ZonguldakTurkey

Personalised recommendations